Drug Trial Radar · NCT04518410
ACTIV-2: A Study for Outpatients With COVID-19
Last checked: Nov 20, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,044
Actual
Start
Aug 19, 2020
Primary completion
Apr 7, 2022
Study completion Jun 20, 2023
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eli Lilly and Company; Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Brii Biosciences Limited; AstraZeneca; Sagent Pharmaceuticals; Synairgen Research Ltd.; Bristol-Myers Squibb; SAb Biotherapeutics, Inc.
- First posted
- Aug 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. In Phase II, participants in the study will be treated with either a study drug or with placebo. In protocol version 7.0, participants in Phase III of the study will be treated with either a study drug or active comparator drug. Participants assigned to the bamlanivimab agent/placebo arm and will have 28 days of intensive follow-up following study drug administration, followed by limited follow-up through 24 weeks in phase II and in phase III. All other investigational agents and their corresponding placebo arms will involve 28 days of intensive follow-up, followed by limited follow-up through 72 weeks in phase II and phase III. Additional study visits may be required, depending on the agent.
Conditions
- Coronavirus
- Covid19
Interventions
bamlanivimab 7000mgBiological
Administered by single IV infusion. Participants are no longer being randomized to this intervention.
BRII-196+BRII-198Biological
1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
AZD7442 (IV)Biological
300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
AZD7442 (IM)Biological
Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
SNG001Drug
1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
CamostatDrug
200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
BMS-986414 + BMS-986413Biological
Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.
SAB-185 (3,840 Units/kg)Biological
Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
SAB-185 (10,240 Units/kg)Biological
Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
CASIRIVIMAB + IMDEVIMABDrug
600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.
Placebo for Bamlanivimab 7000mgDrug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for Bamlanivimab 700mgDrug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for BRII-196+BRII-198Drug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for SNG001Drug
Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Placebo for CamostatDrug
200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Placebo for SAB-185 (low dose)Drug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for BMS-986414 + BMS-986413Drug
Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.
Placebo for AZD7442 (IV)Drug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for AZD7442 (IM)Drug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Placebo for SAB-185 (high dose)Drug
Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
bamlanivimab 700mgBiological
Administered by single IV infusion. Participants are no longer being randomized to this intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- COVID-19 Symptom Duration (Phase 2)Time frame: Up to Day 28
- Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 3
- Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 7
- Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 14
- Number of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 2)Time frame: Thru Day 28
- Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phase 3)Time frame: Thru Day 28
- Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 3)Time frame: Thru Day 28
Locations
252 sites in 9 countries. Site status is shown where the registry gives one.
Pinnacle Research Group (Site 1082), 321 E. 10th Street
Anniston, Alabama
North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B
Athens, Alabama
University of Alabama at Birmingham (Site 1005), 908 20th Street South
Birmingham, Alabama
Cullman Clinical Trials (Site 1140), 501 Clark St. NE.
Cullman, Alabama
Jasper Summit Research, LLC. (Site 1056), 1280 Summit
Jasper, Alabama
Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211
Phoenix, Arizona
University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410
Tucson, Arizona
Omnibus Clinical Research (Site 1253), 3340 W. Ball Road, Ste. I
Anaheim, California
Franco A. Felizarta MD (Site 1174), 3535 San Dimas St.
Bakersfield, California
Clearview Medical Research LLC. (Site 1251), 2714 Hidaway Ave., Ste. 103
Canyon Country, California
St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd.
Fullerton, California
University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer
La Jolla, California
Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320
La Mesa, California
Atella Clinical Research (Site 1111), 5451 La Palma Avenue
La Palma, California
Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C
Loma Linda, California
University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349
Los Angeles, California
UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100
Los Angeles, California
Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100
Los Angeles, California
VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way
Mather, California
Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5
Modesto, California
Hoag Memorial Hospital Presbyterian (Site 1200), 1 Hoag Dr.
Newport Beach, California
Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210
Northridge, California
University of California Irvine (Site 1083), 843 Health Sciences Road
Orange, California
FOMAT Medical Research (Site 1136), 300 South A Street
Oxnard, California
Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive
Rancho Mirage, California
Paradigm Research (Site 1150), 3652 Eureka Way
Redding, California
Riverside Medical Clinic (Site 1232), 7117 Brockton Ave.
Riverside, California
University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd.
Sacramento, California
Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave.
San Bernardino, California
University of California San Diego (Site 1002), 220 Dickinson Street
San Diego, California
Zion Medical Center (Site 1063), 4647 Zion Avenue
San Diego, California
VA San Diego Health System (Stie 1127), 3350 La Jolla
San Diego, California
University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84
San Francisco, California
San Francisco Research Institute (Site 1210), 2435 Ocean Ave.
San Francisco, California
Stanford University (Site 1213), 1201 Welch Road
Stanford, California
Millennium Clinical Trials (Site 1260), 550 Saint Charles Dr., Ste. 208
Thousand Oaks, California
Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301
Thousand Oaks, California
Harbor UCLA (Site 1022), 1124 West Carson Street
Torrance, California
Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101
Westminster, California
University of Colorado (Site 1007), 12401 East 17th Avenue
Aurora, Colorado
Showing 40 of 252 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.